GCP
ITOS

GSA Capital Partners’s iTeos Therapeutics ITOS Stock Holding History

GSA Capital Partners’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-56,887
Closed -$340K – 1938
2025
Q1 		$340K Buy
+56,887
New +$418K 0.03% 1058
2024
Q4 		– Sell
-25,787
Closed -$263K – 1804
2024
Q3 		$263K Buy
+25,787
New +$393K 0.02% 1285
2024
Q2 		– Sell
-15,451
Closed -$211K – 1831
2024
Q1 		$211K Sell
15,451
-31,981
-67% -$348K 0.02% 1393
2023
Q4 		$519K Buy
+47,432
New +$470K 0.04% 769
2023
Q2 		– Sell
-13,251
Closed -$180K – 1723
2023
Q1 		$180K Buy
+13,251
New +$237K 0.02% 1276

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's ITOS Position: Q2 2025 in Review

GSA Capital Partners sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 56,887 shares — an estimated $340K sold.

GSA Capital Partners first reported a position in ITOS in Q1 2023 and held it in 5 quarters. The position peaked at $519K in Q4 2023. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • GSA Capital Partners reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • GSA Capital Partners sold 56,887 iTeos Therapeutics shares in Q2 2025, an estimated $340K.
  • GSA Capital Partners first reported a position in iTeos Therapeutics in Q1 2023 and held it in 5 quarters.
  • GSA Capital Partners's iTeos Therapeutics position peaked at $519K in Q4 2023.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.